🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. CX-072

    CytomX Therapeutics

    Solid Tumor

    phase 2 small molecule terminated

    2 trials

  2. CX-2009

    CytomX Therapeutics

    Solid Tumor, Adult

    phase 2 small molecule terminated

    1 trial

  3. CX-2009

    CytomX Therapeutics

    Neoplasms

    phase 2 small molecule completed

    1 trial

  4. CX-2029

    CytomX Therapeutics

    Solid Tumor, Adult

    phase 2 small molecule completed

    1 trial

  5. CYCLOPHOSPHAMIDE , RITUXIMAB , AB-101, FLUDARABINE

    Artiva Biotherapeutics

    Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Sjögren’s Disease (SjD)

    phase 2 small molecule active

    1 trial

  6. CYCLOPHOSPHAMIDE, Paclitaxel 6 mg/mL concentrate for solution for infusion, Doxorubicin 2 mg/ml Concentrate for Solution for Infusion, DURVALUMAB, Oleclumab_IJB2

    The George Institute

    Luminal B Breast Cancer

    phase 2 small molecule active

    1 trial

  7. CYD Dengue Vaccine

    United Therapeutics Europe Ltd

    Dengue

    phase 2 mab completed

    1 trial

  8. CYSTAGON 150 mg hard capsules

    The George Institute

    Infectious diseases of respiratory system (COVID-19)

    phase 2 small molecule active

    1 trial

  9. CYSTAGON 50 mg hard capsules

    The George Institute

    Pulmonary Tuberculosis

    phase 2 small molecule active

    1 trial

  10. CaPre (TM)

    Grace Therapeutics

    Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial

  11. Cabazitaxel Accord 20 mg/ml concentrate for solution for infusion, Lutathera 370 MBq/mL solution for infusion, Xofigo 1100 kBq/mL solution for injection, Lynparza 150 mg film-coated tablets, Docetaxel Aurovitas 20 mg/ml concentrado para solución para perfusión, BAY 1841788

    Ningbo Cancer Hospital

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  12. Cabergoline 1 MG

    Monte Rosa Therapeutics

    Lactation Suppressed

    phase 2 small molecule completed

    1 trial

  13. Cadonilimab

    The First People's Hospital of Lianyungang

    Lung Cancer

    phase 2 small molecule active

    1 trial

  14. Cadonilimab

    Second Affiliated Hospital of Soochow University

    Immunotherapy

    phase 2 small molecule active

    1 trial

  15. Cadonilimab

    The First People's Hospital of Lianyungang

    Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  16. Cadonilimab

    The First People's Hospital of Lianyungang

    Immunotherapy

    phase 2 small molecule active

    1 trial

  17. Calcium Gluconate

    United Therapeutics Europe Ltd

    Trauma

    phase 2 small molecule active

    1 trial

  18. Calquence 100 mg hard capsules, IMBRUVICA 420 mg film-coated tablets, IMBRUVICA 140 mg hard capsules, IMBRUVICA 140 mg hard capsules, BRUKINSA 80 mg hard capsules, Lisaftoclax, Calquence 100 mg hard capsules, MabThera 500 mg concentrate for solution for infusion, Lisaftoclax, Lisaftoclax

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

    phase 2 small molecule active

    1 trial

  19. Camidanlumab Tesirine

    ADC Therapeutics SA

    Relapsed Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  20. Camostat Mesilate

    United Therapeutics Europe Ltd

    Severe Acute Respiratory Syndrome

    phase 2 small molecule completed

    1 trial

  21. Camrelizumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  22. Camrelizumab

    The First People's Hospital of Lianyungang

    Lung Cancer, Nonsmall Cell

    phase 2 small molecule active

    1 trial

  23. Camrelizumab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  24. Camrelizumab

    The First People's Hospital of Lianyungang

    Lung Neoplasms

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources